收藏切换
Research progress on nanoscale drug delivery system of resiquimod for tumor treatment
收藏切换
PDF
Peng-xin LI1, 2, Xiao-huan WANG2, Ting-ting GONG2, Xiang-tao WANG1, 2, *
Acta Pharmaceutica Sinica | 2025, 60(3) : 700 - 710
Less
收藏切换
Acta Pharmaceutica Sinica | 2025, 60(3): 700-710
Reviews
Research progress on nanoscale drug delivery system of resiquimod for tumor treatment
Full
Peng-xin LI1, 2, Xiao-huan WANG2, Ting-ting GONG2, Xiang-tao WANG1, 2, *
Affiliations
  • 1. School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China
  • 2. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China
Published: 2025-03-12 doi: 10.16438/j.0513-4870.2024-0706
Outline
收藏切换

Resiquimod (R848) belongs to the class of weak base organic compounds that are derivatives of imidazole quinoline and is a potent agonist of Toll-like receptor (TLR) 7/8. R848 can be considered an effective immune adjuvant as it has the ability to activate different immune cells and regulate innate and adaptive immunity. A number of researches done recently have reported R848 potent anti-tumor capacity, especially when combined with other cytotoxic therapies. Nonetheless, some hurdles remain with the clinical use of R848 such as its limited ability to reach the tumor and likelihood of inflammation and autoimmune responses which might result from repeated delivery of high dosages of the drug. Nanoscale drug delivery systems may overcome some of these challenges. Various nanoformulations, including liposomes, polymeric nanoparticles, biocarriers, inclusion compound, metal-organic frameworks and inorganic nanoparticles, as well as several R848 prodrugs or derivatives-baesd nanoparticles, have been incorporated into present R848 delivery platforms. This article reviews the physicochemical properties, immune regulatory mechanisms and nano drug delivery systems of R848, in order to provide reference and support for anti-tumor research and new drug development.

resiquimod  /  antitumor  /  nano drug delivery system  /  Toll-like receptor agonist  /  immunotherapy
Peng-xin LI, Xiao-huan WANG, Ting-ting GONG, Xiang-tao WANG. Research progress on nanoscale drug delivery system of resiquimod for tumor treatment[J]. Acta Pharmaceutica Sinica, 2025 , 60 (3) : 700 -710 . DOI: 10.16438/j.0513-4870.2024-0706
Year 2025 volume 60 Issue 3
PDF
253
121
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2024-0706
  • Receive Date:2024-07-24
  • Online Date:2025-11-06
  • Published:2025-03-12
Article Data
Affiliations
History
  • Received:2024-07-24
  • Revised:2024-12-06
Funding
Affiliations
    1. School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China
    2. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2024-0706
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT